Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

CPhI Worldwide experts propose new FDA Quality metrics system and recommend Critical Formulation Attributes

CPhI
Posted on: 26 Sep 16

Continuous processing at a ‘tippin point’, with CDMO implementation over next 3-years, but the industry needs a better definition of what ‘continuous’ means

SUMMARY of part i: 

Girish Malhotra President at EPCOT International:

  • The pharmaceutical industry’s biggest shortcoming is a lack of manufacturing innovation
  • Continuous manufacturing needs a proper definition, and is very unlikely for nearly all APIs (as volumes are too low) and the business case is not justified
  • Contract Manufactures, with similar chemistries, will be first with continuous manufacturing

 

Ajaz Hussain, Insight, Advice & Solutions LLC

  • Human factors need to be more closely considered in designing manufacturing processes – using behavioural economics will help improve practices Industry is often trapped in a “file first, figure it out later mindset” and simply try’s meet standards not improve quality
  • Broader adoption of PAT-based continuous manufacturing system by brand and by a couple of major generic and CDMO’s should be more prominently evident in the next three years.
  • Continuous manufacturing of injectables is a major opportunity to overcome the risk of drug shortages.
  • There is a key need to advance educational and training programmes in India and China to advance PAT and continuous processing here

 

Prabir K Basu, Consultant, Mt. Prospect, IL, U.S.A. & Thomas Friedli, Professor, Institute of Technology Management, University of St.Gallen, Switzerland

  • Metrics used to measure the performance of a pharmaceutical operation should be systems oriented – and not lagging indicators measuring symptoms (e.g. batch failure rate etc)
  • The important components of a true operational excellence program (OPEX) are continuous improvement, management commitment, and employee involvement. In principle, there is an excellent match of the key components of OPEX and those of an ideal quality system. Therefore, it makes tremendous sense to develop and integrate the metrics for OPEX implementation with an appropriate metrics for “Quality” for pharmaceutical manufacturing operations
  • Team proposes new metrics that will help the FDA to establish a clear standard for review and inspection allowing for a risk-based regulatory approach, transforming quality oversight from a qualitative to a quantitative risk-based process.

 

Brian Carlin, Director Open Innovation at FMC

  • All excipients are potentially critical, especially when subject to cumulative changes throughout the product lifecycle
  • A quality culture will seek to control excipient-related special cause variation before an out of specification excursion. Most excipient-related impact on manufacturability will not be known at time of filing.
  • Continuous monitoring of impact from all excipients throughout the lifecycle is more important than a one-off arbitrary binary classification during development. The importance of all attributes and parameters should be evaluated for impact, and re-evaluated as new information becomes available.

 

Amsterdam, 26 September 2016: CPhI Worldwide, (#cphiww) organised by UBM EMEA, today announces the findings of part i of the 2016 CPhI Annual Report on potential new approaches to improve quality and manufacturing process in pharmaceutical production ahead of CPhI Worldwide 2016 in Barcelona. Five World-renowned experts – Ajaz Hussain, Girish Malhotra, Brian Carlin, Pabir Basu & Thomas Friedli – propose improved methods to how we evaluate and consider quality in the pharmaceutical industry, making a number of key recommendations.

The overall findings reveal there are a number of improvements industry and the regulators can and should make to shift the industry from just meeting standards towards instilling continuous improvement and quality cultures across the board – which the panel predict will vastly improve overall quality and reduce manufacturing errors.

Prabir Basu, independent consultant and Prof Thomas Friedli of the University of St Gallen review a new systems based approach to quality metrics in their article – following the University receiving an FDA grant to undertake this. The goal is to recommend a measurement system based on St.Gallen’s Operational Excellence model, which encourages improved quality rather than lagging indicators that measure symptoms.  The team, which also includes the Dublin Institute of Technology, state that these new metrics will ‘help the FDA to establish a clear standard for review and inspection, allowing for a risk-based regulatory approach, transforming quality oversight from a qualitative to a quantitative risk-based process’. 

Furthermore, Brian Carlin, Director of Open Innovation at FMC warns that excipient risk cannot be fully assessed during development, as product and process changes, including scale-up, have the propensity to change the risk profile. Excipient criticality may be dependent on variations and process changes that occur during manufacturing, which will be unknown at the time of filing. He added, ‘Continuous monitoring of impact from all excipients throughout the lifecycle is more important than a one-off arbitrary binary classification during development. The importance of all attributes and parameters should be evaluated for impact, and re-evaluated as new information becomes available’.

Emphasising the panel’s concern regarding the need to shift towards quality cultures and away from binary measures of product failure, Ajaz Hussain, CEO at Insight Advice & Solutions LLC states that the “file first, figure it out later” mindset is a fundamental part of the problem. He believes that companies that implement QbD and PAT early in development will see the greatest benefits and have the capabilities to “file first”. He added, ‘Broader adoption of PAT-based continuous manufacturing system by brand and by a couple of major generic and CDMO’s should be more prominently evident in the next three years.’

Ajaz believes the industry is now at a ‘tipping point’ with the first adopters of continuous processing having been included in NDAs, and an excellent opportunity now exists for the manufacture of injectables and we should expect more progress over the next three years. However, he argues the ability to manufacture continuous, while significant, is, in fact, a business decision.

Similarly, Girish Malhotra, President at EPCOT International, suggests that whilst there is much excitement around continuous processing, we must better define what it is we mean by continuous – as in terms of APIs, very few products have the scale to be manufactured truly continuously. There simply isn’t the volumes needed and the industry greatest shortcoming is its overall record of manufacturing technology innovation. He commented: ‘All said and done each company producing APIs or their formulations has to justify and use the most cost efficient technology (batch, campaigned batch or continuous) to produce products that are economic and deliver the same quality all the time. Regulators can only regulate and assure product quality. They can suggest the technologies and methods companies should consider for their products. However, companies have to justify use of such technologies. Excellence comes from with in the companies rather than outsiders.’

Chris Kilbee, Group Director Pharma at CPhI: “The findings in this report will be disused further at CPhI Worldwide during the CPhI annual report media debate, but what is clear is that whilst the industry is making significant improvements to overall quality, our experts believe that continuous improvement programmes and on-going analysis are more important to instilling a quality culture than simply striving to achieve minimum regulatory standards. What’s really exciting is that over the next few years we should see a shift towards harmonised standards and more advance manufacturing. By implementing the recommendations from our panel, the pharma industry will advance more quickly, develop better and safer drugs and realise the full potential of lower cost and higher quality manufacturing.”

For a copy of the full articles in the CPhI Annual Report 2016 – released at CPhI Worldwide in Barcelona (4-6th October) – please visit http://www.cphi.com/europe/cphi-annual-report

 

 

-ENDS-

 

Notes to editors

 

About CPhI

CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, Korea, China, India, Japan, Southeast Asia, Istanbul and Russia, and co-locates with ICSE for contract services, P-MEC for machinery, equipment & technology, InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com.

For more information visit: www.cphi.com

The UBM EMEA annual schedule of Pharmaceutical events includes: CPhI, ICSE, P-MEC and InnoPack Worldwide (4-6 October, 2016, Fira de Barcelona Gran Via, Barcelona, Spain); CPhI & P-MEC India (21-23 November, 2016, BEC and BKC Exhibition and Convention Centres, Mumbai, India), Pharmapack Europe (01-02 February, 2017); CPhI Istanbul (8-10 March, 2017 at the IFC Istanbul Expo Center, Istanbul, Turkey); CPhI, P-MEC and Innopack South East Asia (22-24 March, 2017 at the Jakarta International Expo- Jakarta, Indonesia); CPhI Russia (28 March – 30 March, 2017 at JSC VDNH (VVC), Pavilion 75, Hall A, Moscow); CPhI, ICSE, P-MEC, BioPh and InnoPack Japan (19-21 April, 2017 at the Big Sight Exhibition Centre- Tokyo); InformEx (16-18 May, 2017); CPhI China and P-MEC (20-22 June, 2017 at SNIEC, Shanghai, China); CPhI Korea (23-25 August, 2016);

About UBM EMEA

UBM EMEA connects people and creates opportunities for companies across five continents to develop new business, meet customers, launch new products, promote their brands, and expand their market. Through premier brands such as TFM&A, Internet World, IFSEC, MD&M, CPhI, Cruise Shipping Miami, the Concrete Show, and many others, UBM Live exhibitions, conferences, awards programs, publications, Websites, and training and certification programs are an integral part of the marketing plans of companies across more than 20 industry sectors.

For media enquiries, please contact:

Alex Heeley or Nadine Caillaux

De Facto Communications

T: +44 (0) 203 735 8168

E: a.heeley@defacto.com / n.caillaux@defacto.com

Editor's Details

Nadine Caillaux
De Facto Communications
www.defacto.com
2037358168
n.caillaux@defacto.com

Last updated on: 26/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.